2024
GLP1R Gene Expression and Kidney Disease Progression
Triozzi J, Yu Z, Giri A, Chen H, Wilson O, Ferolito B, Ikizler T, Akwo E, Robinson-Cohen C, Gaziano J, Cho K, Phillips L, Tao R, Pereira A, Hung A, Muralidhar S, Moser J, Deen J, Tsao P, Gaziano J, Hauser E, Kilbourne A, Matheny M, Oslin D, Churby L, Whitbourne S, Brewer J, Shayan S, Selva L, Pyarajan S, Cho K, DuVall S, Brophy M, Stephens B, Connor T, Argyres D, Assimes T, Hung A, Kranzler H, Aguayo S, Ahuja S, Alexander K, Androulakis X, Balasubramanian P, Ballas Z, Beckham J, Bhushan S, Boyko E, Cohen D, Dellitalia L, Faulk L, Fayad J, Fujii D, Gappy S, Gesek F, Greco J, Godschalk M, Gress T, Gupta S, Gutierrez S, Harley J, Hamner M, Hurley R, Iruvanti P, Jacono F, Jhala D, Kinlay S, Landry M, Liang P, Liangpunsakul S, Lichy J, Mahan C, Marrache R, Mastorides S, Mattocks K, Meyer P, Moorman J, Morgan T, Murdoch M, Norton J, Okusaga O, Oursler K, Poon S, Rauchman M, Servatius R, Sharma S, Smith R, Sriram P, Strollo P, Tandon N, Villareal G, Walsh J, Wells J, Whittle J, Whooley M, Wilson P, Xu J, Yeh S, Bast E, Dryden G, Hogan D, Joshi S, Lo T, Morales P, Naik E, Ong M, Petrakis I, Rai A, Yen A. GLP1R Gene Expression and Kidney Disease Progression. JAMA Network Open 2024, 7: e2440286. PMID: 39453656, DOI: 10.1001/jamanetworkopen.2024.40286.Peer-Reviewed Original ResearchConceptsGenetic association studiesKidney disease progressionRisk of kidney disease progressionVeterans Affairs Million Veteran ProgramAssociation studiesGenetic risk scoreMillion Veteran ProgramGLP-1RAsDisease progressionIncident end-stage kidney diseaseBody mass indexGlycemic controlGene expressionVeteran ProgramObesity statusMain OutcomesUnadjusted modelsGlucagon-like peptide 1 receptor agonistsStudy participantsPeptide 1 receptor agonistsAbsence of diabetesMass indexMedian follow-upRisk scoreGenotype-Tissue Expression projectDexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study
Petrakis I, Nolen T, Vandergrift N, Hirsch S, Krystal J, De Vivo M, Sabados J, Pisani E, Newcomb J, Kosten T. Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study. American Journal On Addictions 2024 PMID: 39152094, DOI: 10.1111/ajad.13637.Peer-Reviewed Original ResearchPathophysiology of posttraumatic stress disorderAlcohol use disorderSubjective effects of alcoholEffects of alcoholUse disorderComorbid alcohol use disorderAlcohol cue reactivityPosttraumatic stress disorderCrossover laboratory studyCue reactivityAlcohol cravingNoradrenergic dysregulationStress disorderBlood pressureSubjective effectsEthanol administrationClinically significant adverse effectsPharmacotherapeutic approachesTest daysReceptor agonistsPotential treatmentDouble-blind fashionCravingDrinking alcoholDisordersThe Impact of High-Potency Synthetic Opioids on Pharmacotherapies for Opioid Use Disorder: A Scoping Review
Jegede O, De Aquino J, Hsaio C, Caldwell E, Funaro M, Petrakis I, Muvvala S. The Impact of High-Potency Synthetic Opioids on Pharmacotherapies for Opioid Use Disorder: A Scoping Review. Journal Of Addiction Medicine 2024, 18: 499-510. PMID: 39356620, PMCID: PMC11449257, DOI: 10.1097/adm.0000000000001356.Peer-Reviewed Original ResearchNonmedical opioid useOpioid use disorderOpioid useWithdrawal symptomsTreatment outcomesSymptoms prior to treatmentUse disorderRisk of precipitated withdrawalLow-dose buprenorphineSynthetic opioidsPotency synthetic opioidsConclusions Current evidencePrecipitated withdrawalRisk of overdoseDosing strategiesPharmacological interactionsClinical significanceDecreased riskWeb of ScienceOpioidInclusion criteriaCurrent evidenceClinical implicationsMOUDPainThe combination of donepezil and cognitive training for improving treatment outcomes for alcohol use disorder: Design of a randomized controlled trial
Yoon G, Sofuoglu M, Petrakis I, Pittman B, Bell M. The combination of donepezil and cognitive training for improving treatment outcomes for alcohol use disorder: Design of a randomized controlled trial. Contemporary Clinical Trials 2024, 145: 107657. PMID: 39111388, PMCID: PMC11423257, DOI: 10.1016/j.cct.2024.107657.Peer-Reviewed Original ResearchCognitive remediation therapyAlcohol use disorderAlcohol use disorder treatment outcomesNeurocognitive functionCombination of donepezilRemediation therapyUse disorderTreatment outcomesDevelopment of alcohol use disordersReduce heavy drinking daysHeavy drinking daysGlobal neurocognitive functioningImprove neurocognitive functionEnhanced neurocognitive functionImprove cognitive functionRandomized controlled trialsReduce alcohol consumptionNeurobiological evidenceDrinking daysNeurocognitive function scoresCognitive trainingVA Connecticut Healthcare SystemCognitive functionImprove treatment outcomesCognitive impairmentMedial prefrontal cortex neurotransmitter abnormalities in posttraumatic stress disorder with and without comorbidity to major depression
Swanberg K, Prinsen H, Averill C, Campos L, Kurada A, Krystal J, Petrakis I, Averill L, Rothman D, Abdallah C, Juchem C. Medial prefrontal cortex neurotransmitter abnormalities in posttraumatic stress disorder with and without comorbidity to major depression. NMR In Biomedicine 2024, 37: e5220. PMID: 39054694, DOI: 10.1002/nbm.5220.Peer-Reviewed Original ResearchPosttraumatic stress disorderMedial prefrontal cortexStress disorderPosttraumatic stress disorder patientsPosttraumatic stress disorder diagnosisChronic psychiatric conditionImpact of psychiatric comorbiditiesComorbid MDDPrefrontal cortexDepressive disorderTraumatic stressorsPsychiatric conditionsMDDPsychiatric comorbiditiesNeurotransmitter abnormalitiesConcentrations of glutamateMetabolite abnormalitiesHealthy controlsDisordersPattern of abnormalitiesParticipantsGlutamateIn vivo protonMetabolic abnormalitiesDepressionA Systematic Review Evaluating PTSD Treatment Effects on Intermediate Phenotypes of PTSD
Palmisano A, Meshberg-Cohen S, Petrakis I, Sofuoglu M. A Systematic Review Evaluating PTSD Treatment Effects on Intermediate Phenotypes of PTSD. Psychological Trauma Theory Research Practice And Policy 2024, 16: 768-783. PMID: 36595460, DOI: 10.1037/tra0001410.Peer-Reviewed Original ResearchPosttraumatic stress disorderBehavioral treatment outcomesEvidence-based treatmentsCognitive controlThreat processingBody of researchPTSD outcomesPTSD treatmentPaucity of researchStress disorderPreliminary supportIntermediate phenotypesTreatment dropoutMethodological limitationsStudy limitationsTreatment effectsCurrent researchTreatment approachesStrong conclusionsNovel treatment approachesEmpirical studyTreatment outcomesTreatment efficacyResearchMemoryHealth correlates of experiential and behavioral avoidance among trauma-exposed veterans
Schwartz E, Palmisano A, Petrakis I, Pietrzak R, Sofuoglu M. Health correlates of experiential and behavioral avoidance among trauma-exposed veterans. Journal Of Psychiatric Research 2024, 176: 213-217. PMID: 38878649, DOI: 10.1016/j.jpsychires.2024.06.014.Peer-Reviewed Original ResearchTrauma-exposed veteransExperiential avoidanceBehavioral avoidanceAnxiety symptomsDepressive symptomsMental health outcomesCognitive dysfunctionPhysical healthPhysical health outcomesHealth outcomesQuality of lifeHealth-related dysfunctionTrauma historyPsychosocial functioningCognitive functionAvoidance behaviorOutcome measuresHealth-related quality of lifeTreatment targetDistressExploratory analysisVeteransHealth-related qualityAvoidanceAnxietyAlcohol Use Disorder and Chronic Pain: An Overlooked Epidemic
De Aquino J, Sloan M, Nunes J, Costa G, Katz J, de Oliveira D, Ra J, Tang V, Petrakis I. Alcohol Use Disorder and Chronic Pain: An Overlooked Epidemic. American Journal Of Psychiatry 2024, 181: 391-402. PMID: 38706339, PMCID: PMC11521207, DOI: 10.1176/appi.ajp.20230886.Peer-Reviewed Original ResearchConceptsAlcohol use disorderChronic painAUD studiesChronic pain disordersChronic pain outcomesRisk of relapseAlcohol withdrawal syndromeAssessment of painHigher levels of alcohol consumptionLevels of alcohol consumptionWithdrawal syndromePain disordersPain outcomesAcute toleranceNeurobiological changesClinical significanceUse disorderPainClinical relevanceSelf-reportAlcohol intoxicationAlcohol consumptionGeneral populationMedical conditionsNarrative reviewCognitive processing therapy (CPT) versus individual drug counseling (IDC) for PTSD for veterans with opioid use disorder maintained on buprenorphine
Petrakis I, Meshberg‐Cohen S, Nich C, Kelly M, Claudio T, Jane J, Pisani E, Ralevski E. Cognitive processing therapy (CPT) versus individual drug counseling (IDC) for PTSD for veterans with opioid use disorder maintained on buprenorphine. American Journal On Addictions 2024, 33: 525-533. PMID: 38624259, DOI: 10.1111/ajad.13557.Peer-Reviewed Original ResearchCognitive processing therapyIndividual drug counselingPosttraumatic stress disorderOpioid use disorderSubstance use disordersDrug counselingProcessing therapyPTSD symptomsUse disorderCognitive processing therapy groupEvidence-based trauma-focused psychotherapiesSelf-reported PTSD symptomsPosttraumatic stress disorder symptomsPosttraumatic stress disorder treatmentRemission of PTSD symptomsPosttraumatic Stress Disorder ChecklistComorbid opioid use disorderTrauma-focused psychotherapyTrauma-focused treatmentRates of comorbidityTreatment group differencesPCL-5Stress disorderGroup differencesRandomized clinical trialsProblem Opioid Use Among US Military Veterans: Prevalence, Correlates, and Psychiatric Characteristics
Na P, Petrakis I, Krystal J, Pietrzak R. Problem Opioid Use Among US Military Veterans: Prevalence, Correlates, and Psychiatric Characteristics. Journal Of Addiction Medicine 2024, 18: 313-318. PMID: 38498625, PMCID: PMC11150085, DOI: 10.1097/adm.0000000000001286.Peer-Reviewed Original ResearchInstrumental activities of daily livingInstrumental activities of daily living disabilityLifetime suicide attemptsProblem opioid useUS military veteransUS veteransPsychiatric characteristicsSuicide attemptsMilitary veteransAssociated with black race/ethnicityActivities of daily livingNational Health and ResilienceLifetime alcohol use disorderMental health morbidityPosttraumatic stress disorderMental health disordersAlcohol use disorderNon-Hispanic race/ethnicityMultivariate logistic regression modelNationally representative sampleOpioid useLogistic regression modelsInstrumental activitiesHealth morbidityDaily livingThe Management of Posttraumatic Stress Disorder and Acute Stress Disorder: Synopsis of the 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline.
Schnurr P, Hamblen J, Wolf J, Coller R, Collie C, Fuller M, Holtzheimer P, Kelly U, Lang A, McGraw K, Morganstein J, Norman S, Papke K, Petrakis I, Riggs D, Sall J, Shiner B, Wiechers I, Kelber M. The Management of Posttraumatic Stress Disorder and Acute Stress Disorder: Synopsis of the 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Annals Of Internal Medicine 2024, 177: 363-374. PMID: 38408360, DOI: 10.7326/m23-2757.Peer-Reviewed Original ResearchConceptsClinical practice guidelinesU.S. Department of Veterans AffairsDepartment of Veterans AffairsVeterans AffairsPosttraumatic stress disorderManagement of posttraumatic stress disorderAcute stress disorderExternal group of expertsPractice guidelinesDefense Clinical Practice GuidelinesStress disorderPatient-centered careIndividual health outcomesRevised CPGDepartment of Defense Clinical Practice GuidelinesVideo teleconferencingStrength of evidenceQuality of lifeCo-occurring conditionsHealth outcomesPatient perspectiveEvidence-basedPosttraumatic stress disorder treatmentSystematic searchCognitive processing therapyWritten exposure therapy for veterans with co-occurring substance use disorders and PTSD: Study design of a randomized clinical trial
Meshberg-Cohen S, Cook J, Bin-Mahfouz A, Petrakis I. Written exposure therapy for veterans with co-occurring substance use disorders and PTSD: Study design of a randomized clinical trial. Contemporary Clinical Trials 2024, 139: 107475. PMID: 38365173, DOI: 10.1016/j.cct.2024.107475.Peer-Reviewed Original ResearchWritten exposure therapyPosttraumatic stress disorderEvidence-based psychotherapiesSubstance use disordersExposure therapyReduce symptoms of posttraumatic stress disorderSymptoms of posttraumatic stress disorderPTSD specialty clinicRates of posttraumatic stress disorderCo-occurring substance use disordersComorbid posttraumatic stress disorderSubstance use disorder outcomesDays of substance useTreatment-seeking veteransSubstance use disorder treatmentStress disorderAddiction outcomesTherapist involvementAddiction programsSUD treatmentSubstance useTrauma treatmentRandomized clinical trialsWriting conditionsHomework assignmentsProblematic Alcohol Use Trajectories in U.S. Military Veterans during a Public Health Crisis: Results from a 3-year, Nationally Representative, Longitudinal Study
Na P, Fischer I, Petrakis I, Pietrzak R. Problematic Alcohol Use Trajectories in U.S. Military Veterans during a Public Health Crisis: Results from a 3-year, Nationally Representative, Longitudinal Study. Psychiatric Quarterly 2024, 95: 157-171. PMID: 38319532, PMCID: PMC11521206, DOI: 10.1007/s11126-024-10067-w.Peer-Reviewed Original ResearchConceptsDrug use disordersProblematic alcohol useAlcohol use trajectoriesLow social supportAdverse childhood experiencesAlcohol useGreater household incomeSocial supportUS veteransLongitudinal studyNational Health and ResilienceLatent growth mixture modelingU.S. military veteransHousehold incomeGrowth mixture modelingNon-household membersCOVID-19 pandemicVeterans StudyUse disorderMilitary veteransChildhood experiencesPublic health crisisPsychosocial characteristicsPrevention effortsVeteransThe role of neurosteroids in posttraumatic stress disorder and alcohol use disorder: A review of 10 years of clinical literature and treatment implications
Peltier M, Verplaetse T, Altemus M, Zakiniaeiz Y, Ralevski E, Mineur Y, Gueorguieva R, Picciotto M, Cosgrove K, Petrakis I, McKee S. The role of neurosteroids in posttraumatic stress disorder and alcohol use disorder: A review of 10 years of clinical literature and treatment implications. Frontiers In Neuroendocrinology 2024, 73: 101119. PMID: 38184208, PMCID: PMC11185997, DOI: 10.1016/j.yfrne.2023.101119.Peer-Reviewed Original ResearchPosttraumatic stress disorderAlcohol use disorderStress disorderContext of PTSDPTSD/AUDConcurrent posttraumatic stress disorderUnderlying neurobiological mechanismsUse disordersAlcohol-related variablesNeurobiological mechanismsPTSD diagnosisTreatment developmentTreatment implicationsBody of literatureNovel interventionsClinical literatureRole of neurosteroidsDisordersTreatment outcomesYears of researchAlcohol consumptionExogenous pregnenolonePharmacological treatmentBiological variablesAllopregnanolone
2023
Progesterone Attenuates the Stress Response in Individuals with Alcohol Dependence and Post-Traumatic Stress Disorder – A Pilot Study
Ralevski E, Newcomb J, Pisani E, DeNegre D, Peltier M, Jane J, Yoon G, Petrakis I. Progesterone Attenuates the Stress Response in Individuals with Alcohol Dependence and Post-Traumatic Stress Disorder – A Pilot Study. Journal Of Dual Diagnosis 2023, 20: 39-51. PMID: 38147491, PMCID: PMC11214330, DOI: 10.1080/15504263.2023.2294989.Peer-Reviewed Original ResearchAlcohol use disorderStress-induced cravingCognitive performanceNegative affectNeutral scriptsStress disorderPost-traumatic stress disorderComorbid alcohol use disorderTraumatic Stress DisorderMeasures of cravingCurrent alcohol use disorderPositive emotionsTrauma scriptsPhysiological measuresCravingStress-induced symptomsTest sessionsPTSDAnxietyAffectUse disordersLaboratory sessionsCocaine dependenceAlcohol dependenceIndividualsComorbid alcohol use disorder and posttraumatic stress disorder: A proof‐of‐concept randomized placebo‐controlled trial of buprenorphine and naltrexone combination treatment
Davis L, Petrakis I, Pilkinton P, Nolen T, Vandergrift N, Hirsch S, Norrholm S, Kosten T. Comorbid alcohol use disorder and posttraumatic stress disorder: A proof‐of‐concept randomized placebo‐controlled trial of buprenorphine and naltrexone combination treatment. Alcohol Clinical And Experimental Research 2023, 47: 1756-1772. PMID: 37468230, DOI: 10.1111/acer.15155.Peer-Reviewed Original ResearchComorbid alcohol use disorderAlcohol use disorderPosttraumatic stress disorderPlacebo-controlled trialWorld Health OrganizationReceptor antagonismOpioid receptorsUse disordersExtended-release injectable naltrexoneKappa-opioid receptor antagonistStress disorderClinician-Administered PTSD ScalePrimary composite outcomeEffective pharmacologic treatmentOpioid receptor antagonistOpioid receptor antagonismMu-opioid receptorsCombination of buprenorphineBinary primary outcomeTimeline Follow-BackAUD outcomesBuprenorphine 2Injectable placeboPrimary timepointInjectable naltrexonePositive personality traits moderate persistent high alcohol consumption, determined by polygenic risk in U.S. military veterans: results from a 10-year, population-based, observational cohort study
Na P, Zhou H, Montalvo-Ortiz J, Cabrera-Mendoza B, Petrakis I, Krystal J, Polimanti R, Gelernter J, Pietrzak R. Positive personality traits moderate persistent high alcohol consumption, determined by polygenic risk in U.S. military veterans: results from a 10-year, population-based, observational cohort study. Psychological Medicine 2023, 53: 7893-7901. PMID: 37642191, DOI: 10.1017/s003329172300199x.Peer-Reviewed Original ResearchDeveloping Researchers with Expertise in Sex as a Biological Variable through SCORE Career Enhancement Core Center Programs
Zakiniaeiz Y, Peltier M, Mineur Y, Gueorguieva R, Picciotto M, Petrakis I, Cosgrove K, McKee S. Developing Researchers with Expertise in Sex as a Biological Variable through SCORE Career Enhancement Core Center Programs. Journal Of Women's Health 2023, 32: 852-857. PMID: 37585509, PMCID: PMC10457604, DOI: 10.1089/jwh.2023.0015.Peer-Reviewed Original ResearchThe Current Status of Medical Student Education on Opioids
Jegede O, Na P, Petrakis I, Muvvala S. The Current Status of Medical Student Education on Opioids. 2023, 121-138. DOI: 10.1093/oxfordhb/9780197618431.013.5.Peer-Reviewed Original ResearchTrajectories of alcohol consumption in U.S. military veterans: Results from a 10-year population-based longitudinal study
Na P, Montalvo-Ortiz J, Petrakis I, Krystal J, Polimanti R, Gelernter J, Pietrzak R. Trajectories of alcohol consumption in U.S. military veterans: Results from a 10-year population-based longitudinal study. Drug And Alcohol Dependence 2023, 246: 109833. PMID: 36963160, PMCID: PMC10811960, DOI: 10.1016/j.drugalcdep.2023.109833.Peer-Reviewed Original ResearchConceptsAlcohol consumption groupCurrent mental health treatmentDysphoric arousal symptomsMental health treatmentUS veteransAlcohol consumptionHealth treatmentConsumption groupArousal symptomsYounger agePopulation-based longitudinal studyPublic health problemLongitudinal studyExcessive alcohol consumptionAlcohol use disorderPosttraumatic stress disorderU.S. military veteransMedical comorbiditiesChronic courseNational HealthClose monitoringUse disordersHealth problemsVeterans StudyStress disorder